A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ

Trial Profile

A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Cenicriviroc (Primary) ; Pioglitazone
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 01 Oct 2015 Results will be presented at the AASLD Annual Meeting, as per Tobira media release.
    • 11 Aug 2015 Positive results from this study will be presented at a medical meeting later this year, as per Tobira media release.
    • 11 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top